Home / Norway / Nykode Therapeutics ASA
Nykode Therapeutics ASA
No short position is open on this share today.
0.00% of the capital sold short
0 disclosing funds
30 disclosures on record
Evolution of the disclosed total
0%0.5%1%1.5%
Oct 2025Jan 2026Apr 2026Jul 2026
August 7, 2024 today
Open positions
No fund discloses a short position on this share today. The history below keeps the trace of the ones that existed.
History of disclosures
| Date | Fund | % of capital | End of publication |
|---|---|---|---|
| November 4, 2025 | GSA Capital Partners LLP | 0.59% | November 18, 2025 |
| October 21, 2025 | GSA Capital Partners LLP | 0.69% | November 4, 2025 |
| October 13, 2025 | GSA Capital Partners LLP | 0.78% | October 21, 2025 |
| October 2, 2025 | GSA Capital Partners LLP | 0.89% | October 13, 2025 |
| August 29, 2025 | GSA Capital Partners LLP | 0.99% | October 2, 2025 |
| August 15, 2025 | GSA Capital Partners LLP | 1.09% | August 29, 2025 |
| July 28, 2025 | GSA Capital Partners LLP | 1.18% | August 15, 2025 |
| June 11, 2025 | Connor, Clark & Lunn Investment Management Ltd. | 0.69% | July 9, 2025 |
| May 15, 2025 | Connor, Clark & Lunn Investment Management Ltd. | 0.70% | May 19, 2025 |
| April 22, 2025 | GSA Capital Partners LLP | 1.21% | May 15, 2025 |
| April 9, 2025 | GSA Capital Partners LLP | 1.11% | April 22, 2025 |
| April 3, 2025 | GSA Capital Partners LLP | 1.00% | April 9, 2025 |
| March 27, 2025 | GSA Capital Partners LLP | 0.90% | April 3, 2025 |
| February 12, 2025 | Citadel Advisors LLC | 0.59% | February 26, 2025 |
| December 16, 2024 | GSA Capital Partners LLP | 0.81% | February 12, 2025 |
| December 16, 2024 | Citadel Advisors LLC | 0.61% | February 12, 2025 |
| December 11, 2024 | Connor, Clark & Lunn Investment Management Ltd. | 0.60% | December 16, 2024 |
| December 10, 2024 | GSA Capital Partners LLP | 0.72% | December 11, 2024 |
| December 10, 2024 | Citadel Advisors LLC | 0.51% | December 11, 2024 |
| December 4, 2024 | Connor, Clark & Lunn Investment Management Ltd. | 0.52% | December 10, 2024 |
| November 22, 2024 | Millennium International Management LP | 0.53% | November 25, 2024 |
| November 6, 2024 | GSA Capital Partners LLP | 0.60% | November 22, 2024 |
| November 1, 2024 | AQR Capital Management, LLC | 0.50% | November 6, 2024 |
| October 28, 2024 | GSA Capital Partners LLP | 0.51% | November 1, 2024 |
| September 25, 2024 | Arrowstreet Capital, Limited Partnership | 0.51% | October 28, 2024 |
| August 28, 2024 | PDT Partners, LLC | 0.50% | September 10, 2024 |
| August 27, 2024 | Qube Research & Technologies Limited | 0.53% | August 28, 2024 |
| August 22, 2024 | Qube Research & Technologies Limited | 0.56% | August 23, 2024 |
| August 21, 2024 | Qube Research & Technologies Limited | 0.64% | August 22, 2024 |
| August 7, 2024 | Qube Research & Technologies Limited | 0.50% | August 21, 2024 |
Other companies sold short in Norway
- Desert Control AS 2.28% of the capital sold short
- Bakkafrost 1.70% of the capital sold short
- Hexagon Composites 1.64% of the capital sold short
- Tomra Systems 1.59% of the capital sold short
- 2020 Bulkers 1.24% of the capital sold short
- Borr Drilling Limited 1.23% of the capital sold short
- Zaptec ASA 1.20% of the capital sold short
- VÅR Energi ASA 1.17% of the capital sold short
- Grieg Seafood 1.16% of the capital sold short
- Magnora 1.00% of the capital sold short
- SED Energy Holdings PLC 0.99% of the capital sold short
- Envipco Holding N.V. 0.92% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Nykode Therapeutics ASA, source Finanstilsynet, data as at November 4, 2025, https://www.quivad.com/action/nykode-therapeutics-asa